Alesta Therapeutics: Lead Program, Ale1, Being Developed in Hypophosphatasia With Plans to Enter Clinical Development in 2025
Alesta Therapeutics:主導項目Ale1,正在針對低磷酸酶血癥開發,計劃於2025年進入臨牀研發。
Alesta Therapeutics: Lead Program, Ale1, Being Developed in Hypophosphatasia With Plans to Enter Clinical Development in 2025
Alesta Therapeutics:主導項目Ale1,正在針對低磷酸酶血癥開發,計劃於2025年進入臨牀研發。
使用瀏覽器的分享功能,分享給你的好友吧